Avanos Medical (NYSE:AVNS) Stock Rating Lowered by Wall Street Zen
by Renee Jackson · The Cerbat GemAvanos Medical (NYSE:AVNS – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.
Other equities research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.
Get Our Latest Research Report on Avanos Medical
Avanos Medical Trading Up 0.1%
Shares of AVNS stock opened at $24.64 on Friday. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $24.72. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The company has a 50-day simple moving average of $14.90 and a two-hundred day simple moving average of $12.89. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -15.59 and a beta of 1.05.
Avanos Medical (NYSE:AVNS – Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. During the same period in the prior year, the firm posted $0.43 EPS. The firm’s quarterly revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Research analysts anticipate that Avanos Medical will post 1.32 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVNS. AQR Capital Management LLC boosted its stake in Avanos Medical by 46.4% in the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock valued at $2,700,000 after acquiring an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Avanos Medical by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after acquiring an additional 1,121 shares during the last quarter. Millennium Management LLC boosted its stake in Avanos Medical by 508.3% in the first quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock valued at $7,849,000 after acquiring an additional 457,703 shares during the last quarter. Empowered Funds LLC boosted its stake in Avanos Medical by 5.4% in the first quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock valued at $2,324,000 after acquiring an additional 8,348 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Avanos Medical by 17.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock valued at $2,018,000 after acquiring an additional 20,541 shares during the last quarter. 95.17% of the stock is currently owned by hedge funds and other institutional investors.
About Avanos Medical
Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.
In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.